Medicines for Europe
Coverage of Medicines for Europe in the Nexus archive.
- EU sieht sich von Trumps neuen Generika-Zöllen nicht betroffen
The European Commission states that EU generic drugs are likely excluded from Trump's proposed 100% tariffs due to the 2025 Turnberry trade agreement, which mandates a 0% duty via the Most-Favored-Nation (MFN) clause. Trump's plan to impose tariffs on generics from 2028 aims to revive U.S. pharmaceutical production, but EU officials emphasize the agreement protects EU exports. The EU warns of potential retaliatory measures if the U.S. violates the accord.
- EU says Trump’s new generic drug tariffs won’t hit its exports
The European Commission claims EU generic medicines will be exempt from Trump’s proposed 100% tariffs starting 2028, citing the 2025 Turnberry trade deal that ensures a 0% most-favored-nation tariff rate. Trump’s plan aims to boost U.S. pharmaceutical production but faces EU assertions that the deal protects European exports from higher levies.
- EU’s off-patent medicines industry calls for industrial strategy at Athens summit [Advocacy Lab]
The EU’s off-patent medicines industry advocates for an industrial strategy at the Athens summit. The Medicines for Europe conference emphasizes Greece’s growing role as a pharmaceutical manufacturing hub ahead of its 2027 EU Council Presidency.